No.45, Guangfu North Road
Hukou Township
Hsinchu City 303
Taiwan
886 3 597 9288
https://www.ubi-pharma.com
Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Chei-Hsiang Chen Ph.D. | Chairperson, President & GM | N/D | N/D | N/D |
Meng Han Xu | Manager of the Finance Department | N/D | N/D | N/D |
Dr. Roger Kuo Ph.D. | Chief Operating Officer | N/D | N/D | N/D |
Jia Wei Hong | Manager of Accounting Department | N/D | N/D | N/D |
Ms. Vivien Fan | Executive VP, Spokesperson of the Administration Center & Director | N/D | N/D | N/D |
Dr. Yan Ning Guo | COO of Pharmaceutical Business Center & Director | N/D | N/D | N/D |
UBI Pharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan. The company offers protein drugs and formulations of molecule products; and develops biobetters and specialty injectables. Its product portfolio includes film coated, Virapine, and Efanzy tablets, as well as Terbutaline; and Levetir concentrate solution for infusion. The company was founded in 2014 and is based in Hsinchu City, Taiwan.
L'ISS Governance QualityScore di UBI Pharma Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.